Searched for
DESH BANDHU GUPTA
Swiggy deliveryman killed in Delhi as SUV hits bikeAccording to Delhi Police, after the incident, the boy and his friend, who is a foreign national allegedly left the car on the spot and fle...- Sell Lupin, target Rs 783: Manas JaiswalSell Lupin Ltd. at a price target of Rs 783 and a stoploss at Rs 863 from entry point.
- Buy Lupin, target Rs 990: Jay ThakkarBuy Lupin Ltd. at a price target of Rs 990.0 and a stoploss at Rs 949 from entry point.
- Sell Lupin, target Rs 875: Dr CK NarayanSell Lupin Ltd. at a price target of Rs 875.0 and a stoploss at Rs 895 from entry point.
- Buy Lupin, target Rs 905: Dr CK NarayanBuy Lupin Ltd. at a price target of Rs 905.0 and a stoploss at Rs 880 from entry point.
- Buy Lupin, target Rs 834: Kunal BothraBuy Lupin Ltd. at a price target of Rs 834 and a stop loss at Rs 795 from entry point.
- Buy Lupin, target Rs 815: Shrikant ChouhanBuy Lupin Ltd. at a price target of Rs 815.0 and a stop loss at Rs 775 from entry point.
- Buy Lupin, target Rs 960: Vikas JainBuy Lupin Ltd. at a price target of Rs 960.0 and a stop loss at Rs 812 from entry point.
- Buy Lupin, target Rs 880: Gaurav BissaBuy Lupin at a price target of Rs 880 and a stop loss at Rs 820 from entry point.
- Lupin gets shareholders nod to raise up to Rs 7,500 croreIn a BSE filing, Lupin said shareholders have approved a proposal today "to raise funds for an amount not exceeding Rs 7,500 crore through ...
- Lupin shares fall over 3% on disappointing Q4 earningsThe stock ended 3.35 per cent lower at Rs 1,690.60 on the BSE. During the day, it slipped 3.95 per cent to Rs 1,680.
- Lupin Q4 profit falls 1% to Rs 547 croreLupin reported over 1 per cent decline in consolidated net profit to Rs 547 crore for the fourth quarter ended March 31, hit by price erosi...
- India's rich list: Top wealth gainers & losers in last 5-7 yearsThe most notable change has been Sun Pharma's Dilip Shanghvi pipping Mukesh Ambani. The list has seen many additions and deletions.
- Lupin eyes 3-fold hike in revenues to $5 billion by 2018Drug major Lupin is eyeing a nearly three-fold increase in its revenues at $5 billion by 2018 as it looks to grow its business organically.
- No plans to sell India business, to be $3 bn company by FY14: LupinWhile assuring the shareholders that it had no plans to sell its India business, drug firm Lupin today said it aims to be a $3-billion firm...
- Lupin acquires majority stake in South African marketing coDrug firm Lupin today said it has acquired a majority stake in a South African marketing company for an undisclosed sum marking its entry i...
- Lupin acquires pharma business of RubaminDrug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
- Lupin picks up majority stake in SymbiotecAs part of its plan to expand in the steroids segment, pharmaceutical firm Lupin on Thursday said it has acquired a majority stake in Symbi...
- Lupin joins hands with SymbiotecLupin on Thursday said it has made an equity investment in Symbiotec Pharmalab, a company focused on steroids, for a majority stake, in a b...
- Govt to share Lupin's migraineThe government's Department of Science and Technology (DST) has committed over Rs 10 crore to support drug maker Lupin's two clinical devel...
Load More
